Population
Diseased myocardium in experimental models and initial clinical studies
Design
Review
Authors
Loading...
Requires caution with PCOs and sulfonylureas in arrhythmia patients; leaves open targeted potassium channel modulation as a research priority.
Modulating potassium channels offers therapeutic potential for cardiac rhythm and function in diseased myocardium, though agents like PCOs and sulfonylureas carry risks of proarrhythmia or exacerbated ischemic dysfunction.
Lynch et al. (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: